<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02330432</url>
  </required_header>
  <id_info>
    <org_study_id>Pulm/Mw/002</org_study_id>
    <nct_id>NCT02330432</nct_id>
  </id_info>
  <brief_title>Mycobacterium w in Patients With Severe Sepsis</brief_title>
  <acronym>MISS</acronym>
  <official_title>Phase IIb Randomized, Double Blind, Two Arm, Controlled Clinical Trial of Mycobacterium W in Combination With Standard Therapy Versus Standard Therapy Alone in Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pandit Bhagwat Dayal Sharma, PGIMS, Rohtak</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St.John's National Academy of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent evidence suggests that sepsis continuum includes an immune paralytic state, which may&#xD;
      play a significant role in sepsis. Mycobacterium w by its TLR4 agonist activity may help in&#xD;
      restoring immunity, thereby improving outcomes in patients with severe sepsis.&#xD;
&#xD;
      In this randomized trial, the investigators propose to evaluate the efficacy of Mw in&#xD;
      patients with severe sepsis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">October 31, 2018</completion_date>
  <primary_completion_date type="Actual">October 31, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>28-day</time_frame>
    <description>28-day all-cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New onset organ dysfunction measured by delta SOFA (maximum minus baseline SOFA)</measure>
    <time_frame>28-day</time_frame>
    <description>Measured by delta SOFA (maximum minus baseline SOFA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>28-day</time_frame>
    <description>Day off the mechanical ventilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-vasopressor withdrawal</measure>
    <time_frame>28-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>28-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>28-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New-onset infection</measure>
    <time_frame>28-day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Mycobacterium w group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the experimental arm (Mw) in addition to standard care will receive single daily dose of 0.3 mL of Mw (heat-inactivated Mw [0.5 × 10^9]; Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Best standard care for sepsis</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mycobacterium w</intervention_name>
    <description>Single daily dose of 0.3 mL of Mw (heat-inactivated Mw [0.5 × 10^9]; Immuvac, Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days</description>
    <arm_group_label>Mycobacterium w group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best standard care</intervention_name>
    <description>Antibiotics as early as possible; Norepinephrine &gt; vasopressin &gt; epinephrine for hypotension; Blood glucose 140-180 mg/dL; DVT and stress ulcer prophylaxis; Low tidal volume mechanical ventilation; Standard VAP, CLABSI prevention bundles</description>
    <arm_group_label>Best standard care</arm_group_label>
    <arm_group_label>Mycobacterium w group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with severe sepsis within 48 hours of first organ dysfunction&#xD;
&#xD;
          -  Cardiovascular system dysfunction: systolic blood pressure ≤90 mm Hg or the mean&#xD;
             arterial pressure ≤70 mm Hg for at least one hour despite adequate fluid resuscitation&#xD;
             or the use of vasopressors to maintain a systolic blood pressure or mean arterial&#xD;
             pressure of &gt;90 and &gt;65 mm Hg, respectively&#xD;
&#xD;
          -  Renal dysfunction: urine output &lt;0.5 ml/kg/hour for two consecutive hours despite&#xD;
             adequate fluid resuscitation&#xD;
&#xD;
          -  Respiratory system dysfunction: PaO2/FiO2 ≤300 or ≤250 if lung sepsis&#xD;
&#xD;
          -  Hematologic dysfunction: platelet count &lt;100,000/mm3 or decrease by 50% in the three&#xD;
             days preceding enrollment&#xD;
&#xD;
          -  Unexplained metabolic acidosis: pH ≤7.30&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Gram-positive culture&#xD;
&#xD;
          -  Only fungal infection as source of sepsis&#xD;
&#xD;
          -  Patients who received cardiopulmonary resuscitation&#xD;
&#xD;
          -  Those on immunosuppressive therapy&#xD;
&#xD;
          -  Those unwilling to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Pulmonary Medicine</name>
      <address>
        <city>Chandigarh</city>
        <state>UT</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Sehgal IS, Agarwal R, Aggarwal AN, Jindal SK. A randomized trial of Mycobacterium w in severe sepsis. J Crit Care. 2015 Feb;30(1):85-9. doi: 10.1016/j.jcrc.2014.08.012. Epub 2014 Aug 28.</citation>
    <PMID>25241089</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 26, 2014</study_first_submitted>
  <study_first_submitted_qc>December 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2015</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Ritesh Agarwal</investigator_full_name>
    <investigator_title>Additional Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

